TUCSON, Ariz., May 8, 2025 — The year 2025 marks a historic milestone for Critical Path Institute^® (C-Path), as the organization celebrates 20 years of transforming the landscape of drug development through collaboration, regulatory science, and next-generation strategies. Continue reading→

Serum Glutamate Dehydrogenase Activity Enables Sensitive and Specific Diagnosis of Hepatocellular Injury in HumansContinue reading→

New CFO to Lead Financial Strategy and Global Compliance at C-PathContinue reading→

Collaboration has culminated in meaningful, lasting changes for the benefit of stakeholders in the electronic collection of clinical outcome assessment data in clinical trialsContinue reading→

TUCSON, Ariz., February 18, 2024 — Critical Path Institute’s® (C-Path)Critical Path for Alpha-1 (CPA-1) consortium today announced the addition of biopharmaceutical companies, Kamada and Sanofi, as its newest members. Continue reading→

New Leadership to Drive Expansion of Collaborative Initiatives and Fundraising Strategies at C-PathContinue reading→

New Funding Opportunity for Drug Development ProjectsContinue reading→

TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B. Helmsley Charitable Trust, a new research grant aimed at developing a novel treatment for type 1 diabetes (T1D). This award is made through TRxA’s Bridging Research and Innovation in Drug Development Grants (BRIDGe) program, which is designed to support academic researchers in traversing the drug development valley of death and advancing new cutting-edge therapeutics from the lab to patients. Continue reading→

C-Path expands its worldwide leadership in accelerating drug development in neurology; seeks additional collaborators to broaden impact.Continue reading→

Dr. Diane Stephenson Promoted to Vice President of Neurology; Dr. Nadine Tatton Welcomed as New Executive Director of CPADContinue reading→